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The classiﬁcation of T-cell and natural-killer- (NK-) cell lymphomas has been updated in the 4th edition of the World Health
Organization (WHO) classiﬁcation of tumors of the haematopoietic and lymphoid tissue published in 2008. Based on recent
epidemiological studies, NK-cell lymphomas occur almost exclusively in Asia and South America, although T-cell lymphomas
appear to occur in the East as commonly as in the West. Due to the low prevalence of this disease, diagnosis and optimal
treatment of patients have not been studied prospectively in large randomized trials. Nevertheless, there has been development
in the understanding of T-cell lymphomas and how they should be managed; FDG-PET emerges as an increasingly important
tool in diagnosis, gene-expression signatures may aid with prognostication in the future, and novel therapies are currently being
studied to improve outcomes in T-cell lymphomas. More work, however, needs to be done, and international collaboration will be
pertinent to deriving meaningful results from future clinical studies.
1.Introduction
T-cell lymphoma and natural-killer- (NK-) cell lymphoma
represent the smaller subsets of non-Hodgkin’s lymphoma
(NHL) that appear to have a geographical predilection to
Asia. In Europe and North America, T-cell and NK-cell
lymphoma account for 5–10% of all cases of NHL whilst in
A sia,thisper c entageisashighas24%[1].T-celllymphomas,
a sag r o u p ,c a r r yap o o r e rp r o g n o s i sc o m p a r e dt ot h e i rBc e l l
counterpart [2]. In the subgroup of patients with a low inter-
national prognostic index (IPI) score of 1-2, 5-year overall
survival (OS) was 55% in those with T-cell lymphomas and
71% in those with B-cell lymphomas, and this diﬀerence in
survival was also reﬂected in patients with higher IPI scores
[3]. T-cell lymphomas, however, represent a heterogeneous
group of diseases with variations in clinical characteristics,
prognosis and response to treatment. This paper reviews the
developments in the understanding of mature peripheral T-
cell lymphoma (PTCL) and its management.
1.1. WHO Classiﬁcation of T-Cell Lymphoma. The 4th edi-
tion of the World Health Organization (WHO) classiﬁcation
of tumours of the haematopoietic and lymphoid tissue pub-
lished in 2008 builds upon the previous edition published
in 2001, and reclassiﬁes clinicopathological entities based
on better understanding from research in the last few years
[4]. The WHO classiﬁcation now contains 22 diﬀerent T-
cell lymphomas, 7 more than the previous classiﬁcation.
These can be subclassiﬁed according to whether they are
predominantly nodal, extranodal, cutaneous, or leukemic
(Table 1). Two new rare EBV-related T-cell diseases aﬀecting
children in Asia or Central/South America are recognized in
this classiﬁcation. These are systemic EBV T-cell lymphopro-
liferative diseases of childhood and hydroa vacciniforme-like
lymphoma. Furthermore, anaplastic large-cell lymphoma
(ALCL) ALK−positive (ALK+) is now recognized as a
distinct entity from the ALCL ALK-negative (ALK−)l y m -
phomas, which occurs in an older population, and which
bears a far worse prognosis [5]. To eliminate redundancy,2 Advances in Hematology
Table 1: List of T-cell lymphomas adapted from the 2008 WHO




(iii) Primary cutaneous CD30+ T-cell lymphoproliferative
disorders
(iv) Primary cutaneous anaplastic large-cell lymphoma
(v) Primary cutaneous γδ T-cell lymphoma
(vi) Primary cutaneous CD8+ aggressive epidermotropic
lymphoma
(vii) Primary cutaneous CD4+ small/medium T-cell lymphoma
Nodal
(i) Angioimmunoblastic T-cell lymphoma
(ii) Anaplastic large-cell lymphoma, ALK positive
(iii) Anaplastic large-cell lymphoma, ALK negative
(iv) Peripheral T-cell lymphoma, NOS
Extranodal
(i) Systemic EBV+ T-cell childhood lymphoproliferative disorder
(ii) Hydroa vacciniforme-like lymphoma
(iii) Extranodal NK/T-cell lymphoma, nasal type
(iv) Enteropathy-associated T-cell lymphoma
(v) Hepatosplenic T-cell lymphoma
(vi) Subcutaneous panniculitis-like T-cell lymphoma
Leukemic
(i) T-cell prolymphocytic leukaemia
(ii)T-cell large-granular lymphocytic leukaemia
(iii) Adult T-cell leukaemia/lymphoma
precursor T-lymphoblastic lymphoma/leukaemia has lost its
“precursor” preﬁx as the term “lymphoblastic” implies this.
Finally, three new variants of cutaneous T-cell lymphoma
(CTCL) were introduced, and these are primary cutaneous
aggressiveepidermotropicCD8+cytotoxicT-celllymphoma,
primary cutaneous gamma-delta T cell lymphoma and
primary cutaneous small/medium CD4+ T-cell lymphoma.
1.2. Epidemiology. PTCL was thought to occur more fre-
quently in Asia. R¨ udiger et al. reported frequencies of PTCL
in Vancouver to be 1.6% of all NHL compared to 18.3% in
Hong Kong [6]. The international PTCL and NKL project
reportedPTCLandNKLratesof5–10%inWesterncountries
compared to 10–20% in Asian countries [5].
It the study, it was also interesting that the incidence
of ALCL (both ALK+ and ALK−) in North America (24%)
was almost four-times higher than in Asia (6%). Data from
Au et al. and our own institution’s suggest that the rate
of PTCL in the East may actually be similar to the West
[7]. The perceived higher rates of PTCL in the East could
perhaps be due to the higher incidence of NKL in the East
and the diﬀerences in diagnostic evaluation [7]. In their
institution, they evaluated 148 consecutive cases of TCL and
NKL and found that these accounted for 10.1% and 6.5%
of all NHL, respectively. We evaluated a total of 780 patients
with malignant lymphomas from 2002 to 2006 and found
that extranodal NKL and PTCL comprised 5.0% (39/780)
and 7.4% (58/780) of all cases [8].
1.3. Clinical Characteristics of TCL. Peripheral T-cell lym-
phoma, not otherwise speciﬁed (PTCL-NOS), Angioim-
munoblastic T-cell lymphoma (AITL), and ALCL are the
most common subtypes and account for up to 74% of
a l lT - c e l ll y m p h o m a s[ 5]. AITL tends to occur in elderly
patients, and patients often present with disseminated lym-
phadenopathy, hepatosplenomegaly, and autoimmune phe-
nomena [9]. ALCL ALK+ typically occurs in young men and
presentation can be nodal or extranodal, involving the skin,
bone, soft tissues, lung, and liver [10]. On the other hand,
ALK ALCL tends to occur in an older population of patients,
the presentation is usually nodal, and the disease runs a
more aggressive clinical course [11]. PTCL-NOS, represents
a heterogeneous category of nodal and extranodal T cell
lymphomas that cannot be grouped into deﬁned entities.
Most present with peripheral lymph-node enlargement, B
symptoms and at diagnosis, the disease is advanced [12].
Other uncommon T-cell lymphomas include enteropa-
thy-associated T-cell lymphoma (EATL) [13], adult T-cell
leukaemia/lymphoma (ATLL) [14], hepatosplenic T-cell
lymphoma (HSTL) [15], and subcutaneous panniculitis-like
T-cell lymphoma (SPTCL) [16]. It is now recognized that
EATL lymphoma consists of two distinct forms: classical or
type I EATL and type II EATL. Type I EATL is associated
with coeliac disease while type II EATL occurs in Asia and
is not associated with coeliac disease [13]. ATLL is caused by
infection with the human T-cell-lymphotropic virus type 1
(HTLV-1), and is rare outside HTLV-I-endemic areas such
as the Caribbean, Japan, and parts of central Africa [14].
HSTL is rare; patients present with hepatosplenomegaly and
systemic symptoms, and in 20% it occurs in the context
of chronic immune suppression [15]. SPTCL occurs more
commonly in women, and is associated with autoimmune
conditions such as systemic lupus erythematosus [16].
1.4. Diagnostic Workup of PTCL. The histopathological
diagnosis of PTCL can prove to be a challenge even for the
experienced pathologist. In addition to standard histological
analysis and immunophenotyping, clinical information is
important in accurately classifying the TCL. To highlight this
point, in the same international T-cell lymphoma study, a
change in diagnosis of PTCL-NOS to ATLL (Adult T-cell
lymphoma/leukaemia) occurred in 38.7% of cases after
pathologists were informed of the patient’s HTLV-1 (human
T-cell leukaemia virus) status [5].
The standard panel of immunostains used in the
workup of a T-cell lymphoma includes CD20, CD2, CD3,
CD4, CD5, CD8, CD30, CD56, TCR-β, TIA-1 (T-cell
intracellular antigen 1), Ki67, and in situ hybridization assay
for EBV (Epstein-Barr virus) encoded RNA (ribonucleic
acid). PTCL-NOS describes a heterogeneous population of
lymphomas of the T-cell lineage, but which does not fulﬁll
criteria to be classiﬁed into the other categories of TCL. Most
cases are positive for CD4, TCRαβ is expressed and CD5 andAdvances in Hematology 3
7 are frequently downregulated [12]. AITL is characterized
by a polymorphous inﬁltration of the lymph node with
prominent proliferation of high-endothelial venules and
follicular dendritic cells. CD3, CD4, CD10, BCL6, PD1, and
CXCL13 are typically positive, and EBV-positive B cells are
nearly always present [9]. AITL is closely related to follicular
helper T cells and the follicular variant of PTCL, although
they diﬀer genetically [17]. ALCL, ALK+ and ALCL, ALK−
appear similar histologically. There are morphological
variations within ALCL but all have hallmark cells, which
are cells with eccentric, horseshoe, or kidney-shaped nuclei,
often with eosinophilic region near the nucleus. In both
subtypes, CD30, CD2, and CD4 and cytotoxic molecules
including that of perforin, granzyme B, and TIA-1 are
positive. In ALCL, ALK+, the epithelial membrane antigen
(EMA) is characteristically present, and CD3 is negative
in 75% of cases. In ALCL, ALK−, EMA is positive only in
a small proportion of patients, and CD3 is positive [10, 11]
(Table 2).
As mentioned above, Type II EATL is distinct to classical
EATL. In classical or type I EATL, the tumour ulcerates
through the wall of the mucosa, and the intestinal mucosa
surrounding the tumour shows enteropathy comprising
villous atrophy, crypt hyperplasia, and increased lamina
propria lymphocytes and plasma cells. There are large
cytotoxic T cells that often express CD103 and lose both
CD4 and CD8 markers, and the intraepithelial lymphocytes
adjacent may have an identical immunophenotype. In type
II EATL, neoplastic cells are more monotonous with a
distinctive CD3+, CD8+, and CD56+ phenotype. There are
increased intraepithelial lymphocytes, but not the villous
atrophy or crypt hyperplasia typically seen in celiac disease
or classical EATL [13].
1.5. Initial Assessment and Staging of T-Cell Lymphomas.
Staging of PTCL is similar to that of other NHL and involves
a complete physical examination and routine laboratory
tests such as a complete blood count, renal-function test,
liver-function test, and serum lactate dehydrogenase level,
unilateral or bilateral bone marrow examination (aspirate,
trephine, ﬂow cytometry), and radiological imaging with
either computerised tomography (CT) scanning or FDG
PET/CT (ﬂuorodeoxyglucose positron emission tomogra-
phy) assessment.
2.FDGPET/CT
PET scans have an established role in the staging and
assessment of disease response in B-cell lymphomas, with
the ability to diﬀerentiate between ﬁbrosis and active disease
i nar e s i d u a lm a s sa sw e l la si np r o g n o s t i c a t i o n[ 18]. In
contrast, the role of PET in T-cell lymphomas continues
to evolve. A recent review of 135 patients with T-cell
lymphomas who underwent PET examination at diagnosis
or response assessment reported variations in PET-positivity
and maximum standardized uptake value (SUV) across the
diﬀerent T-cell-lymphoma subtypes. PET positivity ranged
from 50% in cutaneous ALCL to 78% in AITL to 100% in
ATLL. Of note, 29% of patients had diseases that were not
picked up on diagnostic CT of the neck, chest, abdomen,
and pelvis. The sites that were missed included cutaneous,
subcutaneous,muscularmassesofthescalp,upperandlower
extremities, and lymphadenopathy in the epitrochlear and
popliteal regions, indicating perhaps a role for PET imaging
from vertex to feet for patients with TCL [19].
2.1. Prognostic Indicators in T-Cell Lymphoma. The diﬀerent
histological subtypes of PTCL confer diﬀerent prognoses.
Systemic ALCL portends a better prognosis than non-ALCL
PTCL [20–23], and within the ALCL subpopulation, those
that are ALK-1 positive have a better prognosis than those
that are ALK-1 negative (5-year OS, 70% versus 49%) [5].
The international prognostic index (IPI) initially described
by Shipp et al. [24] was able to separate patients with PTCL-
NOSandsystemicALCLintodistinctprognosticriskgroups;
however, even with low IPI scores, patient with PTCL had
poor outcomes [5].
A separate prognostic model for patients with PTCL-
NOS called the prognostic index for PTCL-U (unspeciﬁed);
PIT, was proposed [25]. In this retrospective analysis of
385 patients with PTCL-U, multivariate analysis showed
that age, performance status, LDH level, and bone marrow
involvement were predictive of survival, and these variables
were used to develop a new prognostic model that could
separate the patients into 4 distinct prognostic groups.
Curiously, neither a high IPI nor PIT score predict for a
pooreroutcomeinAITL[26].Itispostulatedthattheclinical
eﬀects of AITL is due to the dysregulation of the immune
system rather than the direct eﬀects of tumour growth, given
that hypergammaglobulinemia and eosinophilia accompany
this condition, and since IPI and PIT scores generally
reﬂect tumour burden, it was unable to prognosticate in
AITL.Furthermore,recentworkingene-expressionproﬁling
reveals that AITL is closely associated with follicular helper
cells, and that more than 90% of genes in the AITL gene
signature were contributed by nonneoplastic cells. The AITL
gene signature included genes involved in humoral immune
response,recruitmentofinﬂammatorycells,andmodulation
of vasculogenesis and the extracellular matrix [17].
The CTCL have the best 5-year OS; primary cutaneous
ALCL: 90% and subcutaneous panniculitis-like PTCL: 64%.
EATL and hepatosplenic PTCL are associated with particu-
larly dismal prognoses, with reported 5-year survival rates of
only 20% and 7%, respectively.
2.2. Gene-Expression Proﬁling to Better Classify and Risk
Stratify PTCL. Even with the revised WHO classiﬁcation of
tumors and the development of several prognostic models,
PTCL-NOS remains heterogeneous in terms of biology and
outcome. Using microarrays to analyse the gene expression
proﬁles of 59 nodal TCL, Ballester and colleagues have
managed to distinguish between AITL, ALCL, and T-
lymphoblastic lymphoma, well-characterised entities in the
WHO classiﬁcation [27]. With the same technique, they
managed to identify 3 molecular subgroups amongst the
PTCL-NOS: PTCL-U1, PTCL-U2, and PTCL-U3. The genes4 Advances in Hematology
Table 2: Clinical and histological characteristics of the major PTCL subtypes.
Type of PTCL Clinical characteristics Histological features
PTCL-NOS Most present with peripheral lymph-node enlargement,
advanced disease and B symptoms
CD4>CD8
Antigen loss frequent (CD7, CD5, CD4/CD8, CD52)
CD 10−,B C L 6 −,C L C X 1 3 −,P D 1 −
AITL
Patients are middle-aged and elderly and most present with
generalised lymphadenopathy, hepatosplenomegaly. Laboratory
ﬁndings include circulating immune complexes, cold
agglutinins, and haemolytic anaemia








Male predominance (1.5 : 1) and occurs in the ﬁrst three
decades of life. Most patients present with advanced-stage
disease, peripheral and/or abdominal lymphadenopathy. They
often have B symptoms especially fever
CD 30+
ALK translocation is present Majority EMA+
Majority CD2+, CD5+, CD4+, TIA1+, granzyme B+
Majority CD3−,C D 8 −
ALK-negative
ALCL
Compared to ALK+ ALCL, patients are older (40–65 year-old)
and the clinical course is more aggressive. Similar to ALK+
ALCL, patients present with advanced disease, peripheral
and/or abdominal lymphadenopathy, and B symptoms
CD30+ (strong and homogenous staining)
Majority CD3+, CD4+, CD 43+ Minority EMA+
PAX5−
EBV markers EBER and LMP1 negative
overexpressed in PTCL-U1 included genes associated with
a poorer outcome in other tumors such as CCND2 and
interestingly, although not signiﬁcant, the survival of this
group was worse than the other 2 groups. PTCL-U2 was
associated with genes involved in T-cell activation and apop-
tosis; NFKB1 and BCL2, and PTCL-U3, with genes involved
in the IFN/JAK/STAT pathway, possibly shedding light on
the pathogenesis of these tumours. This work, however, is
preliminary, and conﬁrmatory studies are needed.
2.3. Treatment. No randomized phase III trial has been
conducted in PTCL. Thus, by default, Cyclophosphamide,
Doxorubicin, Vincristine, and Prednisolone (CHOP)-like
chemotherapy, is the most common regimen used despite its
lack of eﬃcacy. The international T cell Project conﬁrms the
poor prognosis of patients with PTCL treated with CHOP-
like regimen [5]. To improve the outcomes of these patients,
s e v e r a ls t r a t e g i e sh a v eb e e ni n v e s t i g a t e d .
3.IncreasedDose-Intensity
Chemotherapy Regimens
At least two large studies have shown the utility of a dose-
intense regimen in improving outcomes in aggressive large-
cell lymphomas, including PTCL. The ﬁrst study compared
the ACVBP (doxorubicin, cyclophosphamide, vincristine,
bleomycin, and prednisolone) regimen with CHOP in 635
patients aged between 61 to 69 years of age and included
96 (15%) patients with T-cell lymphomas. The dose-intense
regimen was shown to signiﬁcantly improve 5-year event-
free survival (EFS) and overall survival (OS) (39% versus
29%, P = .005 and 46% versus 38%, P = .036, resp.) [28].
The second study was the NHL-B1 trial of the German high-
grade non-Hodgkin’s lymphoma study group (DHNSL)
and it had a 2-by-2 factorial design and compared 2-
weekly versus a 3-weekly CHOP with or without Etoposide
(CHOEP) in 866 patients under 60 years, of whom 14%
had T-cell lymphoma. In pooled analysis, the addition of
Etoposide to CHOP chemotherapy in this group of patients
signiﬁcantly improved complete response (CR) rates as well
as 5-year EFS (87.6% versus 79.4%, P = .003 and 69.2%
versus 57.6%, P = .004, resp.) although there was no
diﬀerence in OS [29]. These results were further reinforced
in a recent review of all patients with PTCL and NK-cell
lymphoma treated prospectively in phase II or III protocols
of the DHNSL [30]. Nonetheless, these studies were not
designed speciﬁcally to address the optimal regimen in
patients with PTCL, but suggest that a dose-dense approach
is feasible.
Other attempts at increasing dose density in the setting
of PTCL include the use EPOCH (Infusional etoposide,
vincristine, and doxorubicin with bolus cyclophosphamide
and oral prednisolone) [31] and hyper-CVIDD (hyperfrac-
tionated cyclophosphamide, vincristine, dexamethasone,
and liposomal doxorubicin) alternated with methotrexate
and cytarabine [32] regimens. Peng et al. reported the use
of EPOCH in 21 patients with PTCL, the largest study of
EPOCH use in PTCL patients. These patients included seven
patients with PTCL-U, seven with NKT lymphoma, ﬁve
with ALCL, one with mycosis fungoides/Sezary syndrome,
and another with SPTCL. Of these, seven were previously
treated. The overall response rate was 85% (17/20) with
50% (10/20) achieving CR. Grade III/IV neutropenia rate
was 34.3% with no treatment-related mortality in this study
[31]. In a review of 15 patients with HSTL attending the
M.D Anderson Cancer Centre from 1997 to 2007, 4 patients
received hyper-CVIDD alternated with methotrexate and
cytarabine. Of these, 3 achieved CR and subsequently
proceeded with stem-cell transplantation (SCT). Survival
was reported as 11, 13, and 14 months for these patients.
One patient achieved PR and passed away 8 months later
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Table 3: Selected results of high-dose chemotherapy and autologous stem cell transplantation in PTCL.
Study N Regimen Response OS Comments
Retrospective series
Rodr´ ıguez et al. [33] 115 BEAM/BEAC/CVB/Cy + TBI 86% CR, 5% PR 56% at 5y PTCL
Yamazaki et al. [34] 11 CEM/HD-MTX 91% CR, 9% PR 72% at 3y No ALCL
Schetelig et al. [35] 14 Diverse 86% CR 60% at 5y AITL only
Kyriakou et al. [36] 146 Diverse 70% CR, 7% PR 59% at 4y AITL only
Prospective
Rodr´ ıguez et al. [37] 13 BEAM 65% CR, 4% PR 48% at 3y Subgroup analysis
Mercadel et al. [38]4 1 High-dose
CHOP/ESHAP 51% CR, 7% PR 29% at 4y 41% received ASCR
D’ Amore et al. [39] 77 BEAM 71% CR/PR No data 75% received ASCR
Reimer et al. [40] 83 Cy/TBI 58% CR, 8% PR 48% at 3y 66% received ASCR
4. High-Dose Chemotherapy and
Autologous StemCellRescue
Uncontrolled prospective and retrospective studies suggest
that upfront high dose chemotherapy with autologous stem
cell rescue (HDC+ASCR) as consolidation in patients who
attained complete remission following ﬁrst-line therapy may
result in superior disease control and improved OS rates
(Table 3)[ 33–40]. In a retrospective review of 115 patients
with PTCL, the GEL-TAMO group showed that a 5-year
OS rate of 80% was achieved in the 37 patients who were
transplanted in ﬁrst CR compared to 45% in those treated in
a salvage setting [33]. In another retrospective study of 146
patients with AITL undergoing autologous HSCT, patients
transplanted at ﬁrst remission had signiﬁcantly better 2-
year and 4-year progression-free survival (PFS) compared to
those transplanted following chemotherapy-sensitive relapse
(2-year PFS, 70% versus 42%; 4 year PFS, 56% versus 30%).
The estimated OS rates were also better for those who
received a transplant during ﬁrst CR compared to those
transplanted following chemotherapy-sensitive relapse (2-
year OS was 81% versus 60%; 4-year OS was 78% versus
47%) [36]. Reimer et al. conducted the largest prospective
trial on upfront HDC+ASCR for patients with PTCL [40].
Of the 83 patients enrolled, 55 underwent HDC+ASCR.
The estimated 3-year OS rate was 71% for patients who
underwent HDC+ASCR compared to only 11% for those
who did not. However, this was a single-arm study and
about a third of the patients did not undergo HDC+ASCR
because of a variety of reasons, including disease progression
in 24 (29%). This study highlights two important issues.
Firstly, HDC+ASCR following ﬁrst remission shows promise
in improving survival in patients with an estimated 3-year
survivalrateof71%.Thiscomparesfavorablywithpublished
data. However, this strategy is limited by the fact that about
a third of patients suﬀered early disease progression. Thus,
the challenge is in identifying an eﬀective regimen that can
induce a high remission rate so that more patients can
undergo HDC+ASCR. (Table 3)
5. Graft Versus Lymphoma Effect of
Allogeneic Stem CellTransplantation
Historically, allogeneic SCT is associated with a lower
relapse rate than HDC+ASCR in intermediate to high grade
lymphomas.Thegroupsthathavesubsequentlyattemptedto
study the role of allogeneic SCT in patients with PTCL have
generally found that it is feasible, however, the treatment-
associated toxicities are signiﬁcant. A prospective phase II
trialwasconductedon17patientswithrelapsedorrefractory
PTCL, and they were subjected to salvage chemotherapy and
reduced-intensity allogeneic SCT [41]. At a median followup
of 28 months, 12 patients had CR, 1 had partial response
(PR),and1hadstabledisease(SD)status.3-yearOSandPFS
were 80% and 64%, respectively. 8 patients (47%) had CMV
reactivation,6(35%)developedgraftversushostdisease,and
one died of Enterobacter sepsis. In a retrospective review of
77 patients with PTCL who underwent allogeneic SCT, the
5-year OS and event-free survival rates were 57% and 53%
respectively [42]. Notably, the 5-year OS for chemoresistant
patients was 29%, a result that would not be achieved with
conventional approaches alone. Treatment-related mortality,
however, was 33%.
6. Novel Agents
6.1. Anti-Metabolites (Gemcitabine and Pralatrexate). The
addition of anti-metabolites to the treatment of PTCL has
been studied. Gemcitabine, a pyrimidine analogue, has been
added to a CHOP plus etoposide regimen in a pilot study
of 26 patients with newly diagnosed PTCL. The overall
responseratewas77%(20patients),with16(62%)achieving
complete remission or unconﬁrmed complete remission
(uCR). 14 patients (54%) developed grade IV neutropenia,
but there were no treatment-related deaths [43].
Pralatrexate is another antimetabolite, which has gar-
nered much interest in the treatment of PTCL. Pralatrexate is
anantifolateagentthathashighaﬃnityforthereducedfolate
carrier-1(RFC-1),whoseexpressionisinducedbyoncogenes6 Advances in Hematology
H-ras and c-myc, resulting in selective accumulation of the
drug in tumour cells. In a phase I-II study of 51 patients with
both pretreated B- and T-cell lymphoma, Pralatrexate was
seen to induce a higher overall response rate in the T-cell sub
group compared to the B-cell subgroup (54% versus 10%)
[44]. The PROPEL (Pralatrexate in patients with relapsed or
refractory peripheral T-cell lymphoma) study soon followed
as a prospective, phase II, and single-armed study in patients
with PTCL who had a median of 3 cycles of chemotherapy.
Despite having been heavily pretreated, the overall response
rates were a remarkable 27%, with 8% achieving CR or uCR
[45].However,only12%ofpatientshadasustainedresponse
beyond 14 weeks.
6.2. Immunotherapy (Alemtuzumab and Denileukin Diftitox).
Alemtuzumab is a humanized monoclonal antibody against
CD52, which is highly expressed on malignant T cells,
but also in normal B- and T- lymphocytes [46]. It has
been studied in combination with CHOP for the treatment
of PTCL in two phase II studies. The ﬁrst, reported by
Gallamini et al., enrolled 24 patients whilst the second
by Kim et al., had 20 patients [47, 48]. Both showed
high CR rates of 71% and 65%, respectively; however, the
both studies documented serious infective complications.
In the ﬁrst study, a quarter of their patients developed
life-threatening infections, including invasive aspergillosis,
JC viral encephalitis, pneumocystis carinii pneumonia, and
suspected tuberculosis [47]. In the second study, febrile
neutropenia occurred in 55% of patients while 5 patients,
(25%) had CMV reactivation, 3 patients developed CMV
disease (pneumonitis or retinitis), and 2 died of treatment-
related complications, resulting in the premature closure of
the trial [48].
Denileukin diftitox (Dd) is a recombinant fusion protein
containing the IL-2 (Interleukin-2) protein and a truncated
portion of the diphtheria toxin which targets cells expressing
the IL-2 receptor. It was approved by the FDA in 2008
for the treatment of CTCL [49] and is now being actively
studied for its utility in the treatment of PTCL. In a phase
II trial, 27 patients with relapsed/refractory PTCL (CTCL
excluded) were treated with single-agent Dd 3 times weekly
with tumour staging repeated after every 2 cycles [50]. Six
patients (22%) achieved CR and 7 (26%) showed PR. The
median PFS was 6 months after a median of 2.5 prior
therapies. There were no grade 4/5 toxicities reported. Dd
was then combined with CHOP in 49 patients with a 51%
CR rate and a median PFS of 12 months [51]. Again, Dd was
well tolerated, and multicenter randomized Phase III trials
comparing CHOP to Dd-CHOP are in progress.
6.3. Histone Deacetylase Inhibitors (HDACis). Romidepsin
was ﬁrst isolated from the bacteria Chromobacterium vio-
laceum from a soil sample obtained from the Yamagata
prefecture in Japan. It had minimal antibacterial activity
but showed antitumor eﬀect in human cell lines [52]. 43
patients with relapsed PTCL, treated with a median of 4
previous lines of chemotherapy, were given Romidepsin. The
OR rate was 39% (17 patients) and the median duration of
response was 8.3 months [53]. Currently, a phase 2b study
of Romidepsin in progressive or relapsed PTCL is ongoing at
several international centers.
As a class, HDACis are thought to exert their antitumor
eﬀect by modulating gene expression thereby inﬂuencing cell
diﬀerentiation or apoptosis. Both Vorinostat, an oral HDACi
as well as Romidepsin, have been approved by the FDA for
the treatment of CTCL [54, 55].
6.4. Conclusion. T h e r ei ss t i l ls u b s t a n t i a lw o r kt ob ed o n e
in the classiﬁcation, prognostication, and management
of mature T-cell lymphomas. With the advent of high-
throughput sequencing, technology is available to quickly
identify putative genes involved with each subgroup of
TCL, which may allow reﬁnement of the classiﬁcation and
prognostication process. In light of the low incidence of
this tumour, international collaboration will be important
in accruing patients for larger randomised phase III trials to
evaluate the various novel treatment agents.
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